News stories about Brainstorm Cell Therapeutics (NASDAQ:BCLI) have trended somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Brainstorm Cell Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.7672473170422 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of NASDAQ:BCLI traded down $0.02 on Tuesday, reaching $3.35. 11,139 shares of the company traded hands, compared to its average volume of 59,316. Brainstorm Cell Therapeutics has a 52 week low of $2.88 and a 52 week high of $5.18. The stock has a market capitalization of $65.79, a P/E ratio of -12.95 and a beta of 1.86.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings data on Thursday, March 8th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.11. research analysts expect that Brainstorm Cell Therapeutics will post -0.66 EPS for the current fiscal year.
A number of research analysts have recently issued reports on BCLI shares. Maxim Group set a $9.00 price objective on Brainstorm Cell Therapeutics and gave the company a “buy” rating in a research note on Wednesday, March 28th. ValuEngine raised Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th.
COPYRIGHT VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/24/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-brainstorm-cell-therapeutics-bcli-share-price.html.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.